[Chinese Expert Consensus on the Diagnosis and Treatment of Chronic Graft-versus-host Disease (2024)]

Overview

Journal Zhonghua Xue Ye Xue Za Zhi

Specialty Hematology

Date 2024 Sep 22

PMID 39307718

Affiliations

Soon will be listed here.

Abstract

Chronic graft-versus-host disease (cGVHD) is a common and severe complication following allogeneic hematopoietic stem cell transplantation, which significantly impacts patients' survival and quality of life. In recent years, notable progress has been made in the diagnosis, prevention, and treatment of cGVHD, driven by the emergence of novel therapies such as targeted drugs and the advancement of clinical research. This consensus, based on the latest developments in cGVHD research and growing data from evidence-based medicine, has been revised and updated from the "Chinese consensus on the diagnosis and management of chronic graft-versus-host disease (2021)" to better guide clinical practice.

References

Parra Salinas I, Bermudez A, Lopez Corral L, Lopez Godino O, Moles-Poveda P, Martin G . Treatment of steroid-refractory chronic graft-versus-host disease with imatinib: Real-life experience of the Spanish group of hematopoietic transplantation (GETH). Clin Transplant. 2021; 35(5):e14255. DOI: 10.1111/ctr.14255. View

Lin R, Wang Y, Huang F, Fan Z, Zhang S, Yang T . Two dose levels of rabbit antithymocyte globulin as graft-versus-host disease prophylaxis in haploidentical stem cell transplantation: a multicenter randomized study. BMC Med. 2019; 17(1):156. PMC: 6689871. DOI: 10.1186/s12916-019-1393-7. View

Zhu X, Lai X, Luo Y, Shi J, Tan Y, Zheng W . Combination of low-dose mycophenolate mofetil with cyclosporine and methotrexate as GVHD prophylaxis in unrelated donor allogeneic stem cell transplantation. Leuk Res. 2013; 37(9):1046-51. DOI: 10.1016/j.leukres.2013.06.016. View

Pidala J, Vogelsang G, Martin P, Chai X, Storer B, Pavletic S . Overlap subtype of chronic graft-versus-host disease is associated with an adverse prognosis, functional impairment, and inferior patient-reported outcomes: a Chronic Graft-versus-Host Disease Consortium study. Haematologica. 2011; 97(3):451-8. PMC: 3291602. DOI: 10.3324/haematol.2011.055186. View

Kim H, Koreth J, Whangbo J, Nikiforow S, Reynolds C, Stowe P . Organ-specific response after low-dose interleukin-2 therapy for steroid-refractory chronic graft-versus-host disease. Blood Adv. 2022; 6(15):4392-4402. PMC: 9636330. DOI: 10.1182/bloodadvances.2022007773. View

Zhang W, Gui R, Zu Y, Zhang B, Li Z, Zhang Y . Reduced-dose post-transplant cyclophosphamide plus low-dose post-transplant anti-thymocyte globulin as graft-versus-host disease prophylaxis with fludarabine-busulfan-cytarabine conditioning in haploidentical peripheral blood stem cell.... Br J Haematol. 2022; 200(2):210-221. DOI: 10.1111/bjh.18483. View

Zhao K, Lin R, Fan Z, Chen X, Wang Y, Huang F . Mesenchymal stromal cells plus basiliximab, calcineurin inhibitor as treatment of steroid-resistant acute graft-versus-host disease: a multicenter, randomized, phase 3, open-label trial. J Hematol Oncol. 2022; 15(1):22. PMC: 8900437. DOI: 10.1186/s13045-022-01240-4. View

Xu L, Chen H, Chen J, Han M, Huang H, Lai Y . The consensus on indications, conditioning regimen, and donor selection of allogeneic hematopoietic cell transplantation for hematological diseases in China-recommendations from the Chinese Society of Hematology. J Hematol Oncol. 2018; 11(1):33. PMC: 5833104. DOI: 10.1186/s13045-018-0564-x. View

Ji Y, Tang B, Zhu X, Liu H, Song K, Wan X . [Efficacy and safety of ruxolitinib in the salvage treatment of chronic graft versus-host disease]. Zhonghua Yi Xue Za Zhi. 2020; 100(16):1235-1239. DOI: 10.3760/cma.j.cn112137-20190829-01917. View

10.

Busca A, Locatelli F, Marmont F, Audisio E, Falda M . Response to mycophenolate mofetil therapy in refractory chronic graft-versus-host disease. Haematologica. 2003; 88(7):837-9. View

11.

Park S, Kim K, Jang J, Kim S, Kim W, Jung C . Blood concentration of cyclosporine during early post-transplant period may have influence on the occurrence of chronic graft versus host disease in patients who received allogeneic hematopoietic stem cell transplantation. Oncotarget. 2016; 7(37):59892-59901. PMC: 5312356. DOI: 10.18632/oncotarget.10988. View

12.

Wang D, Liu Y, Lai X, Chen J, Cheng Q, Ma X . Efficiency and Toxicity of Ruxolitinib as a Salvage Treatment for Steroid-Refractory Chronic Graft-Versus-Host Disease. Front Immunol. 2021; 12:673636. PMC: 8278571. DOI: 10.3389/fimmu.2021.673636. View

13.

Peng Y, Chen X, Zhang X, Huang K, Liu L, Li H . Mesenchymal stromal cells infusions improve refractory chronic graft versus host disease through an increase of CD5+ regulatory B cells producing interleukin 10. Leukemia. 2014; 29(3):636-46. DOI: 10.1038/leu.2014.225. View

14.

Lei M, Liu L, Wu D . [Progress of chronic graft-versus-host disease]. Zhonghua Xue Ye Xue Za Zhi. 2016; 37(1):79-82. PMC: 7342310. DOI: 10.3760/cma.j.issn.0253-2727.2016.01.018. View

15.

Pidala J, Onstad L, Martin P, Hamilton B, Cutler C, Kitko C . Initial therapy for chronic graft-versus-host disease: analysis of practice variation and failure-free survival. Blood Adv. 2021; 5(22):4549-4559. PMC: 8759136. DOI: 10.1182/bloodadvances.2021005286. View

16.

Agh T, Csanadi M, Voko Z, Webb T, Jeyakumaran D, Trudeau J . Humanistic burden of patients with chronic graft-versus-host disease - systematic literature review of health-related quality of life and functional status. Expert Rev Hematol. 2019; 12(5):295-309. DOI: 10.1080/17474086.2019.1602036. View

17.

Mays J, Fassil H, Edwards D, Pavletic S, Bassim C . Oral chronic graft-versus-host disease: current pathogenesis, therapy, and research. Oral Dis. 2012; 19(4):327-46. PMC: 3561479. DOI: 10.1111/odi.12028. View

18.

Cheng X, Huang R, Fan W, Huang S, Zeng L, Wu T . The tear cytokine panel is a useful biomarker for early diagnosis and severity-evaluating of ocular chronic graft-versus-host disease. Bone Marrow Transplant. 2023; 58(6):732-734. DOI: 10.1038/s41409-023-01952-2. View

19.

Wang Q, Zhang R, Han M . [Advances in the pathogenesis of chronic graft versus host disease]. Zhonghua Xue Ye Xue Za Zhi. 2017; 38(2):167-171. PMC: 7354165. DOI: 10.3760/cma.j.issn.0253-2727.2017.02.017. View

20.

Kitko C, Arora M, DeFilipp Z, Zaid M, Di Stasi A, Radojcic V . Axatilimab for Chronic Graft-Versus-Host Disease After Failure of at Least Two Prior Systemic Therapies: Results of a Phase I/II Study. J Clin Oncol. 2022; 41(10):1864-1875. PMC: 10082302. DOI: 10.1200/JCO.22.00958. View